Bonyl
Primær information
- Handelsnavn:
- Bonyl 500 mg tabletter
- Aktiv bestanddel:
- NAPROXEN
- Tilgængelig fra:
- Orion Corporation
- ATC-kode:
- M01AE02
- INN (International Name):
- NAPROXEN
- Dosering:
- 500 mg
- Lægemiddelform:
- tabletter
- Brugt til:
- Mennesker
- Medicin typen:
- Allopatiske stof
Dokumenter
- for den brede offentlighed:
- Indlægsseddel
-
- for sundhedspersonale:
- Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.
Anmode informationsbrochure for sundhedspersonale.
Lokation
- Fås i:
-
Danmark
- Sprog:
- dansk
Andre oplysninger
Status
- Kilde:
- Lægemiddelstyrelsen - Danish Medicines Agency
- Autorisation status:
- Markedsført
- Autorisationsnummer:
- 12713
- Sidste ændring:
- 02-02-2018
Indlægsseddel
- Adgang til dette dokument er kun tilgængelig for registrerede brugere.
Tilmeld dig nu for fuld adgang
23-7-2018
![Orphan designation: 1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4- c]pyridin-6-yl)ethan-1-one, for the: Treatment of Stargardt's disease](/web/assets/global/img/flags/eu.png)
Orphan designation: 1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4- c]pyridin-6-yl)ethan-1-one, for the: Treatment of Stargardt's disease
Europe - EMA - European Medicines Agency
23-5-2018
Orphan designation: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid , for the: Treatment of acute myeloid leukaemia
Europe - EMA - European Medicines Agency
13-9-2018
Naproxen: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002125/201708
Europe - EMA - European Medicines Agency
29-5-2018
EU/3/18/2014 (IQVIA RDS Ireland Limited)
EU/3/18/2014 (Active substance: 1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one) - Orphan designation - Commission Decision (2018)3381 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/018/18
Europe -DG Health and Food Safety
18-5-2018
EU/3/14/1328 (Roche Registration GmbH)
EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01
Europe -DG Health and Food Safety